Donfrancesco A, Deb G, De Sio L, Cozza R, Castellano A
Department of Oncology, Bambino Gesù Hospital, Rome, Italy.
Acta Haematol. 1996;95(1):66-9. doi: 10.1159/000203951.
Several studies are consistent with the hypothesis that available iron may have some role in promoting tumor cell growth with different biological mechanisms. For this reason, several studies have been carried out to demonstrate the antitumor activity of deferoxamine (DFO), an iron chelator with a high affinity for ferritin-bound iron. In particular, the effects of DFO have been studied in patients with neuroblastoma, where ferritin is in part tumor derived and high concentrations correlate with poor outcome. To date, in vitro and in vivo studies demonstrating the antitumor effects of DFO are very promising, but further investigations are required to establish an exact role for DFO in the treatment of cancer.
可利用的铁可能通过不同生物学机制在促进肿瘤细胞生长中发挥一定作用。因此，已经开展了多项研究来证实去铁胺（DFO）的抗肿瘤活性，DFO是一种对与铁蛋白结合的铁具有高亲和力的铁螯合剂。特别是，已经在神经母细胞瘤患者中研究了DFO的作用，在神经母细胞瘤中，铁蛋白部分源自肿瘤，高浓度与不良预后相关。迄今为止，证明DFO具有抗肿瘤作用的体外和体内研究很有前景，但还需要进一步研究来确定DFO在癌症治疗中的确切作用。
